Lacutamab
- Generic Name
- Lacutamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2187368-16-5
- Unique Ingredient Identifier
- N8O7MY0VNS
- Background
Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 56
- Registration Number
- NCT04984837
- Locations
- 🇫🇷
Chu de Meaux, Meaux, France
🇧🇪Clinique CHC MontLégia, Liège, Belgium
🇧🇪CHU Dinant Godinne - UCL Namur - YVOIR, Yvoir, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath